Imagion Biosystems Secures Nanoparticle Manufacturer

ChemConnection announcement imageImagion Biosystems Limited (Imagion, ASX:IBX) has entered into a Master Service Agreement with ChemConnection BV, a Dutch contract manufacturing organization (CMO) to produce and supply clinical-grade MagSense® nanoparticle formulations for the Company’s planned HER2 breast cancer human clinical studies.
View the ASX announcement, “Imagion Biosystems Secures Nanoparticle Manufacturer.”